Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark N Milton

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Nature Reviews. Drug Discovery|September 1, 2012
The determination and interpretation of the therapeutic index in drug developmentPatrick Y Muller, Mark N Milton
Clinical Pharmacology and Therapeutics|September 26, 2017
Two Case Studies on How Study Designs Can Be Made More Informative Using Modeling and Simulation ApproachesPhilip J Lowe, Martin Fink, Mark N Milton
Current Drug Metabolism|May 17, 2007
Evaluation of drug-transporter interactions using in vitro and in vivo modelsCindy Q Xia, Mark N Milton, Liang-Shang Gan
The AAPS Journal|November 6, 2021
Immunogenicity Risk Assessment for Multi-specific TherapeuticsMark A Kroenke, Mark N Milton, Seema Kumar, et al.
Journal of Pharmaceutical Sciences|April 7, 2004
Disposition and pharmacokinetics of L-N6-(1-iminoethyl)lysine-5-tetrazole-amide, a selective iNOS inhibitor, in ratsJi Y Zhang, Yuefen Wang, Mark N Milton, et al.
Pharmaceutical Research|December 7, 2007
Toxicological protein biomarker analysis--an investigative one-week single dose intravenous infusion toxicity and toxicokinetic study in cynomolgus monkeys using an antibody-cytotoxic conjugate against ovarian cancerFrank Y Hsieh, Elizabeth Tengstrand, Lily Y Li, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 17, 2018
Models and Approaches Describing the Metabolism, Transport, and Toxicity of Drugs Administered by the Ocular RouteJennifer L Dumouchel, Nagendra Chemuturi, Mark N Milton, et al.
Molecular Therapy. Methods & Clinical Development|January 24, 2018
Nonclinical Safety Evaluation of scAAV8-<i>RLBP1</i> for Treatment of <i>RLBP1</i> Retinitis PigmentosaTimothy K MacLachlan, Mark N Milton, Oliver Turner, et al.
Drug Metabolism Letters|July 31, 2010
P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitorJohnny J Yang, Mark N Milton, Shaoxia Yu, et al.
Journal of Clinical Pharmacology|June 6, 2008
PhRMA white paper on ADME pharmacogenomicsJ Andrew Williams, Tommy Andersson, Tommy B Andersson, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Nature Reviews. Drug Discovery|September 1, 2012
The determination and interpretation of the therapeutic index in drug developmentPatrick Y Muller, Mark N Milton
Clinical Pharmacology and Therapeutics|September 26, 2017
Two Case Studies on How Study Designs Can Be Made More Informative Using Modeling and Simulation ApproachesPhilip J Lowe, Martin Fink, Mark N Milton
Current Drug Metabolism|May 17, 2007
Evaluation of drug-transporter interactions using in vitro and in vivo modelsCindy Q Xia, Mark N Milton, Liang-Shang Gan
The AAPS Journal|November 6, 2021
Immunogenicity Risk Assessment for Multi-specific TherapeuticsMark A Kroenke, Mark N Milton, Seema Kumar, et al.
Journal of Pharmaceutical Sciences|April 7, 2004
Disposition and pharmacokinetics of L-N6-(1-iminoethyl)lysine-5-tetrazole-amide, a selective iNOS inhibitor, in ratsJi Y Zhang, Yuefen Wang, Mark N Milton, et al.
Pharmaceutical Research|December 7, 2007
Toxicological protein biomarker analysis--an investigative one-week single dose intravenous infusion toxicity and toxicokinetic study in cynomolgus monkeys using an antibody-cytotoxic conjugate against ovarian cancerFrank Y Hsieh, Elizabeth Tengstrand, Lily Y Li, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 17, 2018
Models and Approaches Describing the Metabolism, Transport, and Toxicity of Drugs Administered by the Ocular RouteJennifer L Dumouchel, Nagendra Chemuturi, Mark N Milton, et al.
Molecular Therapy. Methods & Clinical Development|January 24, 2018
Nonclinical Safety Evaluation of scAAV8-<i>RLBP1</i> for Treatment of <i>RLBP1</i> Retinitis PigmentosaTimothy K MacLachlan, Mark N Milton, Oliver Turner, et al.
Drug Metabolism Letters|July 31, 2010
P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitorJohnny J Yang, Mark N Milton, Shaoxia Yu, et al.
Journal of Clinical Pharmacology|June 6, 2008
PhRMA white paper on ADME pharmacogenomicsJ Andrew Williams, Tommy Andersson, Tommy B Andersson, et al.
Pageof 2